{ "ticker": "CL", "cik": "0000021665", "company": "Colgate-Palmolive Company", "business_type": "industrial", "schema_template": "consumer products (standard industrial template): net sales, cost of sales, gross profit, SG&A, other (income) expense, operating profit, interest, pre-tax income, income taxes, net income including and attributable to noncontrolling interests, net income attributable to Colgate-Palmolive, basic and diluted EPS with weighted shares; full balance sheet with total debt; operating, investing and financing cash flow, capital expenditures, free cash flow, dividends and share repurchases; dividends declared per share; segment net sales and operating profit; and the company's non-GAAP net income and diluted EPS", "reporting_currency": "USD", "converted_to_usd": false, "units": "actual US dollars (not millions); per-share amounts in dollars; share counts in actual shares. Cash flow lines carry the sign the cash flow statement prints (outflows negative).", "units_notes_seen": { "FY2025 10-K consolidated statements of income": "(Dollars in Millions Except Per Share Amounts)", "FY2025 10-K consolidated balance sheets": "(Dollars in Millions Except Share and Per Share Amounts)", "FY2025 10-K consolidated statements of cash flows": "(Dollars in Millions)", "FY2025 10-K consolidated statements of changes in shareholders' equity": "(Dollars in Millions); dividends per share printed in dollars in the row caption", "FY2025 10-K Note 12 earnings per share": "(Dollars in Millions Except Share and Per Share Amounts); share column headed 'Shares (millions)'", "FY2025 10-K Note 14 segment information": "(Dollars in Millions Except Share and Per Share Amounts)", "FY2025 10-K stock repurchases share activity table": "actual shares (page note: Dollars in Millions Except Share and Per Share Amounts)", "FY2025 10-K MD&A non-GAAP net income and EPS reconciliation": "(Dollars in Millions Except Per Share Amounts)", "Q3 2026 10-Q condensed consolidated statements of income": "(Dollars in Millions Except Per Share Amounts) (Unaudited)", "Q3 2026 10-Q condensed consolidated balance sheets": "(Dollars in Millions Except Share and Per Share Amounts) (Unaudited)", "Q3 2026 10-Q condensed consolidated statements of cash flows": "(Dollars in Millions) (Unaudited), nine months ended September 30 only", "Q3 2026 10-Q condensed consolidated statements of changes in shareholders' equity": "(Dollars in Millions) (Unaudited); dividends per share in the row caption", "Q3 2026 10-Q Note 7 earnings per share": "(Dollars in Millions Except Share and Per Share Amounts); share column headed 'Shares (millions)'", "Q3 2026 10-Q Note 11 segment information (incl. capital expenditures and depreciation by segment)": "(Dollars in Millions Except Share and Per Share Amounts) (Unaudited)", "Q3 2026 10-Q MD&A non-GAAP net income and EPS reconciliation": "(Dollars in Millions Except Per Share Amounts)", "Q3 2026 10-Q cover page share count": "actual shares", "Q3 2026 earnings release (Form 8-K exhibit) cash flow and free cash flow": "(Dollars in Millions) (Unaudited)", "March 2026 Form 8-K segment recast exhibit": "(Dollars in Millions) (Unaudited)" }, "adjustments": { "splits_applied": [], "adr_ratio": null, "fx": "none; Colgate-Palmolive reports in US dollars" }, "annual": [ { "fiscal_year": 2025, "label": "FY2025", "period_start": "2025-01-01", "period_end": "2025-12-31", "period_type": "fiscal year", "source_accession": "0000021665-26-000006", "source_form": "10-K", "income_statement": { "net_sales": 20382000000, "cost_of_sales": 8131000000, "gross_profit": 12251000000, "selling_general_and_administrative_expenses": 7903000000, "other_income_expense_net": 123000000, "operating_profit": 3306000000, "non_service_related_postretirement_costs": 55000000, "interest_expense": 267000000, "interest_income": 75000000, "income_before_income_taxes": 3059000000, "provision_for_income_taxes": 798000000, "net_income_including_noncontrolling_interests": 2261000000, "net_income_attributable_to_noncontrolling_interests": 129000000, "net_income": 2132000000, "basic_eps": 2.64, "diluted_eps": 2.63, "goodwill_and_intangible_assets_impairment_charges": 919000000, "basic_shares": 808700000, "diluted_shares": 811100000, "dividends_declared_per_share": 2.08 }, "balance_sheet": { "cash_and_cash_equivalents": 1288000000, "receivables_net": 1675000000, "inventories": 2032000000, "other_current_assets": 714000000, "total_current_assets": 5709000000, "property_plant_and_equipment_net": 4660000000, "goodwill": 3122000000, "other_intangible_assets_net": 1536000000, "deferred_income_tax_assets": 205000000, "other_assets": 1098000000, "total_assets": 16330000000, "debt_payable_within_one_year": 1117000000, "accounts_payable": 2089000000, "accrued_income_taxes": 383000000, "other_accruals": 3264000000, "total_current_liabilities": 6853000000, "long_term_debt": 6871000000, "deferred_income_tax_liabilities": 181000000, "other_liabilities": 2060000000, "total_liabilities": 15965000000, "common_stock": 1466000000, "additional_paid_in_capital": 4322000000, "retained_earnings": 26595000000, "accumulated_other_comprehensive_loss": -3879000000, "treasury_stock_at_cost": -28450000000, "total_colgate_palmolive_shareholders_equity": 54000000, "noncontrolling_interests": 311000000, "total_equity": 365000000, "total_liabilities_and_equity": 16330000000, "total_debt": 7988000000, "common_shares_outstanding": 801239524 }, "cash_flow": { "depreciation_and_amortization": 630000000, "stock_based_compensation_expense": 155000000, "operating_cash_flow": 4198000000, "capital_expenditures": -564000000, "payment_for_acquisitions_net_of_cash_acquired": -293000000, "investing_cash_flow": -817000000, "short_term_borrowing_repayment_net": -989000000, "principal_payments_on_debt": -655000000, "proceeds_from_issuance_of_debt": 1188000000, "dividends_paid": -1823000000, "purchases_of_treasury_shares": -1210000000, "proceeds_from_exercise_of_stock_options": 101000000, "financing_cash_flow": -3256000000, "cash_and_cash_equivalents_end_of_period": 1288000000, "income_taxes_paid": 913000000, "interest_paid": 270000000, "free_cash_flow": 3634000000 }, "segments": { "basis": "Five geographic Oral, Personal and Home Care segments (North America, Latin America, Europe, Asia Pacific, Africa/Eurasia) plus Pet Nutrition, as reported in the FY2025 10-K, before the realignment effective for the quarter ended March 31, 2026. Not comparable segment-by-segment with the 2026 quarterly figures; product-segment totals (Oral, Personal and Home Care; Pet Nutrition) and Corporate are unaffected.", "note": "Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.", "source_accession": "0000021665-26-000006", "north_america": { "net_sales": 4045000000, "operating_profit": 784000000 }, "latin_america": { "net_sales": 4776000000, "operating_profit": 1411000000 }, "europe": { "net_sales": 2962000000, "operating_profit": 748000000 }, "asia_pacific": { "net_sales": 2814000000, "operating_profit": 760000000 }, "africa_eurasia": { "net_sales": 1172000000, "operating_profit": 255000000 }, "pet_nutrition": { "net_sales": 4613000000, "operating_profit": 1064000000 }, "total_oral_personal_and_home_care": { "net_sales": 15769000000, "operating_profit": 3959000000 }, "corporate": { "operating_profit": -1717000000 }, "total": { "net_sales": 20382000000, "operating_profit": 3306000000 } }, "segments_recast_to_2026_structure": { "basis": "The same fiscal year recast by the company to the four-segment structure effective for the quarter ended March 31, 2026 (North America; Latin America; Europe, Middle East & Africa; Asia Pacific), furnished in the company's Form 8-K of March 17, 2026 (accession 0000021665-26-000010). Unaudited. Directly comparable with the 2026 quarterly segment figures.", "source_accession": "0000021665-26-000010", "north_america": { "net_sales": 3679000000, "operating_profit": 790000000 }, "latin_america": { "net_sales": 4776000000, "operating_profit": 1411000000 }, "europe_middle_east_and_africa": { "net_sales": 4276000000, "operating_profit": 938000000 }, "asia_pacific": { "net_sales": 3038000000, "operating_profit": 820000000 }, "pet_nutrition": { "net_sales": 4613000000, "operating_profit": 1064000000 }, "total_oral_personal_and_home_care": { "net_sales": 15769000000, "operating_profit": 3959000000 }, "corporate": { "operating_profit": -1717000000 }, "total": { "net_sales": 20382000000, "operating_profit": 3306000000 } }, "non_gaap": { "adjusted_income_before_income_taxes": 4065000000, "adjusted_net_income": 2996000000, "adjusted_diluted_eps": 3.69, "adjustments_to_net_income": { "goodwill_and_intangible_assets_impairment_charges": 794000000, "erisa_litigation_matter": 53000000, "restructuring_programs": 11000000, "acquisition_related_costs": 7000000 } } }, { "fiscal_year": 2024, "label": "FY2024", "period_start": "2024-01-01", "period_end": "2024-12-31", "period_type": "fiscal year", "source_accession": "0000021665-26-000006", "source_form": "10-K", "income_statement": { "net_sales": 20101000000, "cost_of_sales": 7940000000, "gross_profit": 12161000000, "selling_general_and_administrative_expenses": 7729000000, "other_income_expense_net": 164000000, "operating_profit": 4268000000, "non_service_related_postretirement_costs": 87000000, "interest_expense": 292000000, "interest_income": 67000000, "income_before_income_taxes": 3956000000, "provision_for_income_taxes": 907000000, "net_income_including_noncontrolling_interests": 3049000000, "net_income_attributable_to_noncontrolling_interests": 160000000, "net_income": 2889000000, "basic_eps": 3.53, "diluted_eps": 3.51, "goodwill_and_intangible_assets_impairment_charges": 0, "basic_shares": 819100000, "diluted_shares": 823200000, "dividends_declared_per_share": 2.48 }, "balance_sheet": { "cash_and_cash_equivalents": 1096000000, "receivables_net": 1521000000, "inventories": 1987000000, "other_current_assets": 713000000, "total_current_assets": 5317000000, "property_plant_and_equipment_net": 4422000000, "goodwill": 3272000000, "other_intangible_assets_net": 1756000000, "deferred_income_tax_assets": 195000000, "other_assets": 1084000000, "total_assets": 16046000000, "debt_payable_within_one_year": 660000000, "accounts_payable": 1805000000, "accrued_income_taxes": 403000000, "other_accruals": 2891000000, "total_current_liabilities": 5759000000, "long_term_debt": 7289000000, "deferred_income_tax_liabilities": 343000000, "other_liabilities": 2111000000, "total_liabilities": 15502000000, "common_stock": 1466000000, "additional_paid_in_capital": 4181000000, "retained_earnings": 26145000000, "accumulated_other_comprehensive_loss": -4222000000, "treasury_stock_at_cost": -27358000000, "total_colgate_palmolive_shareholders_equity": 212000000, "noncontrolling_interests": 332000000, "total_equity": 544000000, "total_liabilities_and_equity": 16046000000, "total_debt": 7949000000, "common_shares_outstanding": 812574698 }, "cash_flow": { "depreciation_and_amortization": 605000000, "stock_based_compensation_expense": 135000000, "operating_cash_flow": 4107000000, "capital_expenditures": -561000000, "payment_for_acquisitions_net_of_cash_acquired": 0, "investing_cash_flow": -534000000, "short_term_borrowing_repayment_net": 93000000, "principal_payments_on_debt": -503000000, "proceeds_from_issuance_of_debt": 2000000, "dividends_paid": -1789000000, "purchases_of_treasury_shares": -1739000000, "proceeds_from_exercise_of_stock_options": 638000000, "financing_cash_flow": -3389000000, "cash_and_cash_equivalents_end_of_period": 1096000000, "income_taxes_paid": 933000000, "interest_paid": 302000000, "free_cash_flow": 3546000000 }, "segments": { "basis": "Five geographic Oral, Personal and Home Care segments (North America, Latin America, Europe, Asia Pacific, Africa/Eurasia) plus Pet Nutrition, as reported in the FY2025 10-K, before the realignment effective for the quarter ended March 31, 2026. Not comparable segment-by-segment with the 2026 quarterly figures; product-segment totals (Oral, Personal and Home Care; Pet Nutrition) and Corporate are unaffected.", "note": "Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.", "source_accession": "0000021665-26-000006", "north_america": { "net_sales": 4113000000, "operating_profit": 839000000 }, "latin_america": { "net_sales": 4782000000, "operating_profit": 1526000000 }, "europe": { "net_sales": 2770000000, "operating_profit": 658000000 }, "asia_pacific": { "net_sales": 2858000000, "operating_profit": 812000000 }, "africa_eurasia": { "net_sales": 1095000000, "operating_profit": 253000000 }, "pet_nutrition": { "net_sales": 4483000000, "operating_profit": 965000000 }, "total_oral_personal_and_home_care": { "net_sales": 15618000000, "operating_profit": 4088000000 }, "corporate": { "operating_profit": -784000000 }, "total": { "net_sales": 20101000000, "operating_profit": 4268000000 } }, "segments_recast_to_2026_structure": { "basis": "The same fiscal year recast by the company to the four-segment structure effective for the quarter ended March 31, 2026 (North America; Latin America; Europe, Middle East & Africa; Asia Pacific), furnished in the company's Form 8-K of March 17, 2026 (accession 0000021665-26-000010). Unaudited. Directly comparable with the 2026 quarterly segment figures.", "source_accession": "0000021665-26-000010", "north_america": { "net_sales": 3716000000, "operating_profit": 856000000 }, "latin_america": { "net_sales": 4782000000, "operating_profit": 1526000000 }, "europe_middle_east_and_africa": { "net_sales": 4046000000, "operating_profit": 814000000 }, "asia_pacific": { "net_sales": 3074000000, "operating_profit": 892000000 }, "pet_nutrition": { "net_sales": 4483000000, "operating_profit": 965000000 }, "total_oral_personal_and_home_care": { "net_sales": 15618000000, "operating_profit": 4088000000 }, "corporate": { "operating_profit": -784000000 }, "total": { "net_sales": 20101000000, "operating_profit": 4268000000 } }, "non_gaap": { "adjusted_income_before_income_taxes": 4041000000, "adjusted_net_income": 2962000000, "adjusted_diluted_eps": 3.6, "adjustments_to_net_income": { "restructuring_programs": 73000000 } } }, { "fiscal_year": 2023, "label": "FY2023", "period_start": "2023-01-01", "period_end": "2023-12-31", "period_type": "fiscal year", "source_accession": "0000021665-26-000006", "source_form": "10-K", "income_statement": { "net_sales": 19457000000, "cost_of_sales": 8131000000, "gross_profit": 11326000000, "selling_general_and_administrative_expenses": 7151000000, "other_income_expense_net": 191000000, "operating_profit": 3984000000, "non_service_related_postretirement_costs": 360000000, "interest_expense": 287000000, "interest_income": 55000000, "income_before_income_taxes": 3392000000, "provision_for_income_taxes": 937000000, "net_income_including_noncontrolling_interests": 2455000000, "net_income_attributable_to_noncontrolling_interests": 155000000, "net_income": 2300000000, "basic_eps": 2.78, "diluted_eps": 2.77, "goodwill_and_intangible_assets_impairment_charges": 0, "basic_shares": 827400000, "diluted_shares": 829200000, "dividends_declared_per_share": 1.91 }, "cash_flow": { "depreciation_and_amortization": 567000000, "stock_based_compensation_expense": 122000000, "operating_cash_flow": 3745000000, "capital_expenditures": -705000000, "payment_for_acquisitions_net_of_cash_acquired": 0, "investing_cash_flow": -742000000, "short_term_borrowing_repayment_net": -906000000, "principal_payments_on_debt": -903000000, "proceeds_from_issuance_of_debt": 1495000000, "dividends_paid": -1749000000, "purchases_of_treasury_shares": -1128000000, "proceeds_from_exercise_of_stock_options": 380000000, "financing_cash_flow": -2793000000, "cash_and_cash_equivalents_end_of_period": 966000000, "income_taxes_paid": 937000000, "interest_paid": 280000000, "free_cash_flow": 3040000000 }, "segments": { "basis": "Five geographic Oral, Personal and Home Care segments (North America, Latin America, Europe, Asia Pacific, Africa/Eurasia) plus Pet Nutrition, as reported in the FY2025 10-K, before the realignment effective for the quarter ended March 31, 2026. Not comparable segment-by-segment with the 2026 quarterly figures; product-segment totals (Oral, Personal and Home Care; Pet Nutrition) and Corporate are unaffected.", "note": "Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.", "source_accession": "0000021665-26-000006", "north_america": { "net_sales": 4091000000, "operating_profit": 871000000 }, "latin_america": { "net_sales": 4640000000, "operating_profit": 1417000000 }, "europe": { "net_sales": 2571000000, "operating_profit": 573000000 }, "asia_pacific": { "net_sales": 2782000000, "operating_profit": 767000000 }, "africa_eurasia": { "net_sales": 1083000000, "operating_profit": 254000000 }, "pet_nutrition": { "net_sales": 4290000000, "operating_profit": 806000000 }, "total_oral_personal_and_home_care": { "net_sales": 15167000000, "operating_profit": 3882000000 }, "corporate": { "operating_profit": -704000000 }, "total": { "net_sales": 19457000000, "operating_profit": 3984000000 } }, "segments_recast_to_2026_structure": { "basis": "The same fiscal year recast by the company to the four-segment structure effective for the quarter ended March 31, 2026 (North America; Latin America; Europe, Middle East & Africa; Asia Pacific), furnished in the company's Form 8-K of March 17, 2026 (accession 0000021665-26-000010). Unaudited. Directly comparable with the 2026 quarterly segment figures.", "source_accession": "0000021665-26-000010", "north_america": { "net_sales": 3665000000, "operating_profit": 834000000 }, "latin_america": { "net_sales": 4640000000, "operating_profit": 1417000000 }, "europe_middle_east_and_africa": { "net_sales": 3822000000, "operating_profit": 754000000 }, "asia_pacific": { "net_sales": 3041000000, "operating_profit": 878000000 }, "pet_nutrition": { "net_sales": 4290000000, "operating_profit": 806000000 }, "total_oral_personal_and_home_care": { "net_sales": 15167000000, "operating_profit": 3882000000 }, "corporate": { "operating_profit": -704000000 }, "total": { "net_sales": 19457000000, "operating_profit": 3984000000 } } } ], "quarterly": [ { "fiscal_year": 2026, "fiscal_quarter": 3, "label": "Q3 FY2026", "period_start": "2026-07-01", "period_end": "2026-09-30", "period_type": "three months", "source_accession": "0000021665-26-000048", "source_form": "10-Q", "income_statement": { "net_sales": 5369000000, "cost_of_sales": 2136000000, "gross_profit": 3233000000, "selling_general_and_administrative_expenses": 2111000000, "other_income_expense_net": 34000000, "operating_profit": 1088000000, "non_service_related_postretirement_costs": 24000000, "interest_expense": 62000000, "interest_income": 17000000, "income_before_income_taxes": 1019000000, "provision_for_income_taxes": 240000000, "net_income_including_noncontrolling_interests": 779000000, "net_income_attributable_to_noncontrolling_interests": 28000000, "net_income": 751000000, "basic_eps": 0.94, "diluted_eps": 0.94, "basic_shares": 796900000, "diluted_shares": 799700000, "dividends_declared_per_share": 0.53 }, "balance_sheet": { "cash_and_cash_equivalents": 1527000000, "receivables_net": 1901000000, "inventories": 2182000000, "other_current_assets": 747000000, "total_current_assets": 6357000000, "property_plant_and_equipment_net": 4613000000, "goodwill": 3080000000, "other_intangible_assets_net": 1472000000, "deferred_income_tax_assets": 222000000, "other_assets": 998000000, "total_assets": 16742000000, "debt_payable_within_one_year": 532000000, "accounts_payable": 2096000000, "accrued_income_taxes": 358000000, "other_accruals": 3653000000, "total_current_liabilities": 6639000000, "long_term_debt": 7184000000, "deferred_income_tax_liabilities": 262000000, "other_liabilities": 2017000000, "total_liabilities": 16102000000, "common_stock": 1466000000, "additional_paid_in_capital": 4474000000, "retained_earnings": 27415000000, "accumulated_other_comprehensive_loss": -3866000000, "treasury_stock_at_cost": -29201000000, "total_colgate_palmolive_shareholders_equity": 288000000, "noncontrolling_interests": 352000000, "total_equity": 640000000, "total_liabilities_and_equity": 16742000000, "total_debt": 7716000000, "common_shares_outstanding": 794920513 }, "cash_flow": { "capital_expenditures": -134000000, "depreciation_and_amortization": 159000000 }, "segments": { "basis": "Four geographic Oral, Personal and Home Care segments (North America; Latin America; Europe, Middle East & Africa; Asia Pacific) plus Hill's Pet Nutrition, the structure effective for the quarter ended March 31, 2026; the Q3 2026 10-Q recasts 2025 comparatives to this structure.", "note": "Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.", "source_accession": "0000021665-26-000048", "north_america": { "net_sales": 905000000, "operating_profit": 177000000 }, "latin_america": { "net_sales": 1326000000, "operating_profit": 392000000 }, "europe_middle_east_and_africa": { "net_sales": 1130000000, "operating_profit": 262000000 }, "asia_pacific": { "net_sales": 802000000, "operating_profit": 211000000 }, "pet_nutrition": { "net_sales": 1205000000, "operating_profit": 267000000 }, "total_oral_personal_and_home_care": { "net_sales": 4164000000, "operating_profit": 1042000000 }, "corporate": { "operating_profit": -221000000 }, "total": { "net_sales": 5369000000, "operating_profit": 1088000000 } }, "non_gaap": { "adjusted_income_before_income_taxes": 1049000000, "adjusted_net_income": 777000000, "adjusted_diluted_eps": 0.97, "adjustments_to_net_income": { "strategic_growth_and_productivity_program": 26000000 } } }, { "fiscal_year": 2025, "fiscal_quarter": 3, "label": "Q3 FY2025", "period_start": "2025-07-01", "period_end": "2025-09-30", "period_type": "three months", "source_accession": "0000021665-26-000048", "source_form": "10-Q", "income_statement": { "net_sales": 5131000000, "cost_of_sales": 2082000000, "gross_profit": 3049000000, "selling_general_and_administrative_expenses": 1971000000, "other_income_expense_net": 19000000, "operating_profit": 1059000000, "non_service_related_postretirement_costs": 21000000, "interest_expense": 67000000, "interest_income": 21000000, "income_before_income_taxes": 992000000, "provision_for_income_taxes": 226000000, "net_income_including_noncontrolling_interests": 766000000, "net_income_attributable_to_noncontrolling_interests": 31000000, "net_income": 735000000, "basic_eps": 0.91, "diluted_eps": 0.91, "basic_shares": 807800000, "diluted_shares": 810200000, "dividends_declared_per_share": 0.52 }, "cash_flow": { "capital_expenditures": -155000000, "depreciation_and_amortization": 158000000 }, "segments": { "basis": "Four geographic Oral, Personal and Home Care segments (North America; Latin America; Europe, Middle East & Africa; Asia Pacific) plus Hill's Pet Nutrition, the structure effective for the quarter ended March 31, 2026; the Q3 2026 10-Q recasts 2025 comparatives to this structure.", "note": "Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.", "source_accession": "0000021665-26-000048", "north_america": { "net_sales": 922000000, "operating_profit": 199000000 }, "latin_america": { "net_sales": 1178000000, "operating_profit": 337000000 }, "europe_middle_east_and_africa": { "net_sales": 1115000000, "operating_profit": 243000000 }, "asia_pacific": { "net_sales": 775000000, "operating_profit": 213000000 }, "pet_nutrition": { "net_sales": 1142000000, "operating_profit": 255000000 }, "total_oral_personal_and_home_care": { "net_sales": 3989000000, "operating_profit": 992000000 }, "corporate": { "operating_profit": -189000000 }, "total": { "net_sales": 5131000000, "operating_profit": 1059000000 } }, "non_gaap": { "adjusted_income_before_income_taxes": 992000000, "adjusted_net_income": 735000000, "adjusted_diluted_eps": 0.91 } } ], "year_to_date": { "label": "9M FY2026", "fiscal_year": 2026, "period_start": "2026-01-01", "period_end": "2026-09-30", "period_type": "nine months", "source_accession": "0000021665-26-000048", "source_form": "10-Q", "income_statement": { "net_sales": 16055000000, "cost_of_sales": 6300000000, "gross_profit": 9755000000, "selling_general_and_administrative_expenses": 6316000000, "other_income_expense_net": 370000000, "operating_profit": 3069000000, "non_service_related_postretirement_costs": 70000000, "interest_expense": 186000000, "interest_income": 50000000, "income_before_income_taxes": 2863000000, "provision_for_income_taxes": 682000000, "net_income_including_noncontrolling_interests": 2181000000, "net_income_attributable_to_noncontrolling_interests": 91000000, "net_income": 2090000000, "basic_eps": 2.61, "diluted_eps": 2.61, "basic_shares": 799500000, "diluted_shares": 802200000, "dividends_declared_per_share": 1.59 }, "cash_flow": { "depreciation_and_amortization": 470000000, "stock_based_compensation_expense": 141000000, "operating_cash_flow": 2913000000, "capital_expenditures": -400000000, "payment_for_acquisitions_net_of_cash_acquired": 0, "investing_cash_flow": -381000000, "short_term_borrowing_repayment_net": 947000000, "principal_payments_on_debt": -1087000000, "proceeds_from_issuance_of_debt": 0, "dividends_paid": -1308000000, "purchases_of_treasury_shares": -927000000, "proceeds_from_exercise_of_stock_options": 178000000, "financing_cash_flow": -2272000000, "cash_and_cash_equivalents_end_of_period": 1527000000, "income_taxes_paid": 648000000, "interest_paid": 205000000, "free_cash_flow": 2513000000 }, "segments": { "basis": "Four geographic Oral, Personal and Home Care segments (North America; Latin America; Europe, Middle East & Africa; Asia Pacific) plus Hill's Pet Nutrition, the structure effective for the quarter ended March 31, 2026; the Q3 2026 10-Q recasts 2025 comparatives to this structure.", "note": "Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.", "source_accession": "0000021665-26-000048", "north_america": { "net_sales": 2684000000, "operating_profit": 510000000 }, "latin_america": { "net_sales": 4011000000, "operating_profit": 1211000000 }, "europe_middle_east_and_africa": { "net_sales": 3377000000, "operating_profit": 791000000 }, "asia_pacific": { "net_sales": 2388000000, "operating_profit": 643000000 }, "pet_nutrition": { "net_sales": 3594000000, "operating_profit": 816000000 }, "total_oral_personal_and_home_care": { "net_sales": 12461000000, "operating_profit": 3155000000 }, "corporate": { "operating_profit": -902000000 }, "total": { "net_sales": 16055000000, "operating_profit": 3069000000 } }, "non_gaap": { "adjusted_income_before_income_taxes": 3196000000, "adjusted_net_income": 2359000000, "adjusted_diluted_eps": 2.94, "adjustments_to_net_income": { "strategic_growth_and_productivity_program": 268000000 } }, "prior_year_comparative": { "label": "9M FY2025", "fiscal_year": 2025, "period_start": "2025-01-01", "period_end": "2025-09-30", "period_type": "nine months", "source_accession": "0000021665-26-000048", "source_form": "10-Q", "income_statement": { "net_sales": 15152000000, "cost_of_sales": 6047000000, "gross_profit": 9105000000, "selling_general_and_administrative_expenses": 5833000000, "other_income_expense_net": 58000000, "operating_profit": 3214000000, "non_service_related_postretirement_costs": 116000000, "interest_expense": 203000000, "interest_income": 56000000, "income_before_income_taxes": 2951000000, "provision_for_income_taxes": 685000000, "net_income_including_noncontrolling_interests": 2266000000, "net_income_attributable_to_noncontrolling_interests": 97000000, "net_income": 2169000000, "basic_eps": 2.68, "diluted_eps": 2.67, "basic_shares": 810000000, "diluted_shares": 812800000, "dividends_declared_per_share": 1.56 }, "cash_flow": { "depreciation_and_amortization": 457000000, "stock_based_compensation_expense": 127000000, "operating_cash_flow": 2745000000, "capital_expenditures": -387000000, "payment_for_acquisitions_net_of_cash_acquired": -293000000, "investing_cash_flow": -714000000, "short_term_borrowing_repayment_net": 139000000, "principal_payments_on_debt": -655000000, "proceeds_from_issuance_of_debt": 497000000, "dividends_paid": -1300000000, "purchases_of_treasury_shares": -804000000, "proceeds_from_exercise_of_stock_options": 83000000, "financing_cash_flow": -1895000000, "cash_and_cash_equivalents_end_of_period": 1279000000, "income_taxes_paid": 712000000, "interest_paid": 235000000, "free_cash_flow": 2358000000 }, "segments": { "basis": "Four geographic Oral, Personal and Home Care segments (North America; Latin America; Europe, Middle East & Africa; Asia Pacific) plus Hill's Pet Nutrition, the structure effective for the quarter ended March 31, 2026; the Q3 2026 10-Q recasts 2025 comparatives to this structure.", "note": "Segment net sales and operating profit as reported. Operating profit for each operating segment excludes Corporate items (stock-based compensation, research and development, Corporate overhead, restructuring charges and, in 2025, the goodwill and intangible assets impairment charges), which are shown on the Corporate line.", "source_accession": "0000021665-26-000048", "north_america": { "net_sales": 2745000000, "operating_profit": 583000000 }, "latin_america": { "net_sales": 3528000000, "operating_profit": 1052000000 }, "europe_middle_east_and_africa": { "net_sales": 3204000000, "operating_profit": 706000000 }, "asia_pacific": { "net_sales": 2259000000, "operating_profit": 620000000 }, "pet_nutrition": { "net_sales": 3417000000, "operating_profit": 778000000 }, "total_oral_personal_and_home_care": { "net_sales": 11735000000, "operating_profit": 2961000000 }, "corporate": { "operating_profit": -523000000 }, "total": { "net_sales": 15152000000, "operating_profit": 3214000000 } }, "non_gaap": { "adjusted_income_before_income_taxes": 3027000000, "adjusted_net_income": 2228000000, "adjusted_diluted_eps": 2.74, "adjustments_to_net_income": { "erisa_litigation_matter": 53000000, "acquisition_related_costs": 7000000 } } } }, "trailing_twelve_months": { "label": "TTM ended September 30, 2026", "period_start": "2025-10-01", "period_end": "2026-09-30", "period_type": "trailing twelve months", "source_accession": "0000021665-26-000048", "source_accessions": [ "0000021665-26-000006", "0000021665-26-000048" ], "derivation": "FY2025 (FY2025 10-K) plus the nine months ended September 30, 2026, less the nine months ended September 30, 2025 (both from the Q3 2026 10-Q).", "income_statement": { "net_sales": 21285000000, "cost_of_sales": 8384000000, "gross_profit": 12901000000, "selling_general_and_administrative_expenses": 8386000000, "other_income_expense_net": 435000000, "operating_profit": 3161000000, "income_before_income_taxes": 2971000000, "provision_for_income_taxes": 795000000, "net_income_including_noncontrolling_interests": 2176000000, "net_income": 2053000000, "goodwill_and_intangible_assets_impairment_charges": 919000000 }, "cash_flow": { "operating_cash_flow": 4366000000, "capital_expenditures": -577000000, "dividends_paid": -1831000000, "purchases_of_treasury_shares": -1333000000, "free_cash_flow": 3789000000 } }, "notes": [ "Sources: annual figures for 2025, 2024 and 2023 are from the FY2025 Form 10-K (accession 0000021665-26-000006); quarterly, nine-month and September 30, 2026 balance sheet figures are from the Q3 2026 Form 10-Q (accession 0000021665-26-000048). The 10-K prints balance sheets for December 31, 2025 and 2024 only, so FY2023 carries no balance sheet.", "net_income is net income attributable to Colgate-Palmolive Company, the figure earnings per share are based on; net income including the share attributable to noncontrolling interests is reported separately.", "Weighted basic and diluted share counts are from the earnings per share notes (Note 12 of the 10-K, Note 7 of the 10-Q), printed there in millions. common_shares_outstanding is the count of common shares outstanding: at December 31, 2025 and 2024 from the 10-K's share activity table, and at September 30, 2026 from the 10-Q cover page.", "total_debt is debt payable within one year plus long-term debt as printed on the balance sheet. free_cash_flow is net cash provided by operations less capital expenditures; the company calls this 'free cash flow before dividends' and its Q3 2026 earnings release (Form 8-K, accession 0000021665-26-000047) reports free cash flow before dividends of $2,513 million and $2,358 million for the nine months of 2026 and 2025.", "The 10-Q presents its cash flow statement for the nine-month periods only, so the three-month quarters carry no operating cash flow or free cash flow. Their capital expenditures and depreciation and amortization are the totals of the 10-Q's segment note, which prints the three-month figures; capital expenditures are shown as outflows to match the cash flow statement's sign.", "Dividends declared per share are from the statements of changes in shareholders' equity. The 10-K notes that five dividends were declared in 2024 and four in each of 2025 and 2023, which is why the 2024 per-share figure ($2.48) is higher than 2025's ($2.08).", "2025 operating profit and net income include $919 million of goodwill and intangible assets impairment charges (recorded in Corporate). The nine months of 2026 include $327 million of Strategic Growth and Productivity Program charges in Corporate operating profit ($29 million in the third quarter), most of it in Other (income) expense, net.", "Segments: effective for the quarter ended March 31, 2026 the company realigned its geographic reporting, combining Europe, Africa/Eurasia (excluding Russia and Belarus) and the skin health business (previously in North America) into a new Europe, Middle East & Africa segment, and moving Russia and Belarus into Asia Pacific. Quarterly and nine-month segment figures are on the new four-segment basis, with 2025 comparatives recast by the company in the 10-Q. Each annual period carries two segment views, each labelled with its basis: 'segments' as the FY2025 10-K reported them (five geographic segments), and 'segments_recast_to_2026_structure' from the company's recast furnished on Form 8-K on March 17, 2026 (accession 0000021665-26-000010). Consolidated results, product-segment totals and Corporate are identical in both views; the realignment changed no consolidated figure.", "non_gaap figures are the company's own reconciliations in the 10-K and 10-Q MD&A, which exclude the items listed (impairment, ERISA litigation, restructuring, acquisition-related costs, Strategic Growth and Productivity Program charges). The 10-Q shows no adjustments for the third quarter of 2025, so its non-GAAP figures equal GAAP. The 10-K's reconciliation covers 2025 and 2024 only.", "The trailing-twelve-month view is derived: FY2025 plus the nine months of 2026 less the nine months of 2025. It includes the fourth quarter of 2025, which carried the full $919 million impairment charge (the 2025 nine-month income statement shows none). Per-share figures are not derived for it because the company computes earnings per share independently for each period." ], "uncertainties": [ "Three-month operating cash flow and free cash flow for the third quarters of 2026 and 2025 are not reported: the 10-Q prints cash flows for the nine-month periods only.", "The recast annual segment figures come from an unaudited exhibit furnished on Form 8-K, not from the audited 10-K." ], "headline": { "period": "Q3 FY2026", "period_end_words": "September 30, 2026", "metrics": [ { "label": "Net sales", "format": "usd", "value": 5369000000, "text": "$5.37 billion", "exact": "$5,369,000,000", "compact": "$5.37B", "abs": "$5.37 billion", "prior_value": 5131000000, "prior": "$5.13 billion", "priorabs": "$5.13 billion", "yoy": "up 4.6%", "source": { "array": "quarterly", "field": "income_statement.net_sales", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000021665-26-000048", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000021665-26-000048", "gap_days": 365 } }, { "label": "Net income", "format": "usd", "value": 751000000, "text": "$751 million", "exact": "$751,000,000", "compact": "$751.00M", "abs": "$751 million", "prior_value": 735000000, "prior": "$735 million", "priorabs": "$735 million", "yoy": "up 2.2%", "source": { "array": "quarterly", "field": "income_statement.net_income", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000021665-26-000048", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000021665-26-000048", "gap_days": 365 } }, { "label": "Diluted EPS", "format": "eps", "value": 0.94, "text": "$0.94", "exact": "$0.94", "compact": "$0.94", "abs": "$0.94", "prior_value": 0.91, "prior": "$0.91", "priorabs": "$0.91", "yoy": "up 3.3%", "source": { "array": "quarterly", "field": "income_statement.diluted_eps", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000021665-26-000048", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000021665-26-000048", "gap_days": 365 } }, { "label": "Adjusted diluted EPS", "format": "eps", "value": 0.97, "text": "$0.97", "exact": "$0.97", "compact": "$0.97", "abs": "$0.97", "prior_value": 0.91, "prior": "$0.91", "priorabs": "$0.91", "yoy": "up 6.6%", "source": { "array": "quarterly", "field": "non_gaap.adjusted_diluted_eps", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000021665-26-000048", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000021665-26-000048", "gap_days": 365 } }, { "label": "Gross profit", "format": "usd", "value": 3233000000, "text": "$3.23 billion", "exact": "$3,233,000,000", "compact": "$3.23B", "abs": "$3.23 billion", "prior_value": 3049000000, "prior": "$3.05 billion", "priorabs": "$3.05 billion", "yoy": "up 6.0%", "source": { "array": "quarterly", "field": "income_statement.gross_profit", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0000021665-26-000048", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0000021665-26-000048", "gap_days": 365 } } ], "summary": "Colgate-Palmolive reported net sales of $5.37 billion for Q3 FY2026, the quarter ended September 30, 2026, up 4.6% from a year earlier, and net income attributable to the company of $751 million, up 2.2%. Diluted earnings per share were $0.94 against $0.91 a year earlier; excluding charges under its Strategic Growth and Productivity Program, diluted EPS was $0.97, up 6.6%. Gross profit rose faster than sales, to $3.23 billion, as cost savings and pricing more than covered higher material costs, with much of the gain reinvested in advertising.", "qa": [ { "q": "What were Colgate-Palmolive's net sales in Q3 FY2026?", "a": "Colgate-Palmolive reported net sales of $5.37 billion for Q3 FY2026, the quarter ended September 30, 2026. That is up 4.6% from $5.13 billion in the same quarter a year earlier." }, { "q": "How much did Colgate-Palmolive earn in Q3 FY2026?", "a": "Colgate-Palmolive's net income attributable to the company was $751 million in Q3 FY2026, up 2.2% from $735 million a year earlier. Diluted earnings per share were $0.94, against $0.91." }, { "q": "What was Colgate-Palmolive's adjusted EPS in Q3 FY2026?", "a": "Excluding charges under its Strategic Growth and Productivity Program, Colgate-Palmolive earned $0.97 per diluted share in Q3 FY2026, up 6.6% from $0.91 a year earlier, when the company reported no such adjustments for the quarter. Reported diluted EPS was $0.94." }, { "q": "How much gross profit did Colgate-Palmolive make in Q3 FY2026?", "a": "Colgate-Palmolive's gross profit was $3.23 billion in Q3 FY2026, up 6.0% from $3.05 billion a year earlier, while net sales were up 4.6%." } ] }, "company_details": { "Name": "Colgate Palmolive Co", "Ticker": "CL", "CIK": "0000021665", "Exchange": "NYSE", "State": "New York", "Incorporation": "Delaware", "SIC": "2844", "Office": "Industrial Applications and Services", "Industry": "Perfumes, Cosmetics & Other Toilet Preparations" }, "next_filing": { "predicted_date": "2027-02-22", "predicted_type": "10-K" }, "fiscal_period": { "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "form": "10-Q", "accession": "0000021665-26-000048", "fiscal_year_end": "1231", "source": "facts" }, "source_filings": [ { "role": "annual", "current": false, "form": "10-K", "fiscal_year": 2025, "fiscal_period": "FY", "tag": "FY25", "period_end": "2025-12-31", "filed": "2026-02-23", "accession": "0000021665-26-000006", "url": "https://www.sec.gov/Archives/edgar/data/21665/000002166526000006/cl-20251231.htm", "source": "reported" }, { "role": "quarterly", "current": true, "form": "10-Q", "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "filed": "2026-10-30", "accession": "0000021665-26-000048", "url": "https://www.sec.gov/Archives/edgar/data/21665/000002166526000048/cl-20260930.htm", "source": "facts" } ], "figure_sources": { "about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '#', and the link is documents[] + '#': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.", "documents": { "d1": "https://www.sec.gov/Archives/edgar/data/21665/000002166526000006/cl-20251231.htm", "d2": "https://www.sec.gov/Archives/edgar/data/21665/000002166526000048/cl-20260930.htm" }, "annual": [ { "period_end": "2025-12-31", "income_statement": { "net_sales": "d1#f-73", "cost_of_sales": "d1#f-76", "gross_profit": "d1#f-79", "selling_general_and_administrative_expenses": "d1#f-82", "other_income_expense_net": "d1#f-85", "operating_profit": "d1#f-91", "non_service_related_postretirement_costs": "d1#f-94", "interest_expense": "d1#f-97", "interest_income": "d1#f-100", "income_before_income_taxes": "d1#f-103", "provision_for_income_taxes": "d1#f-106", "net_income_including_noncontrolling_interests": "d1#f-109", "net_income_attributable_to_noncontrolling_interests": "d1#f-112", "net_income": "d1#f-116", "basic_eps": "d1#f-119", "diluted_eps": "d1#f-122", "goodwill_and_intangible_assets_impairment_charges": "d1#f-88", "basic_shares": "d1#f-1639", "diluted_shares": "d1#f-1651", "dividends_declared_per_share": "d1#f-284" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-156", "receivables_net": "d1#f-160", "inventories": "d1#f-162", "other_current_assets": "d1#f-164", "total_current_assets": "d1#f-166", "property_plant_and_equipment_net": "d1#f-168", "goodwill": "d1#f-170", "other_intangible_assets_net": "d1#f-172", "deferred_income_tax_assets": "d1#f-174", "other_assets": "d1#f-176", "total_assets": "d1#f-178", "debt_payable_within_one_year": "d1#f-180", "accounts_payable": "d1#f-182", "accrued_income_taxes": "d1#f-184", "other_accruals": "d1#f-186", "total_current_liabilities": "d1#f-188", "long_term_debt": "d1#f-190", "deferred_income_tax_liabilities": "d1#f-192", "other_liabilities": "d1#f-194", "total_liabilities": "d1#f-196", "common_stock": "d1#f-206", "additional_paid_in_capital": "d1#f-208", "retained_earnings": "d1#f-210", "accumulated_other_comprehensive_loss": "d1#f-212", "treasury_stock_at_cost": "d1#f-214", "total_colgate_palmolive_shareholders_equity": "d1#f-216", "noncontrolling_interests": "d1#f-218", "total_equity": "d1#f-220", "total_liabilities_and_equity": "d1#f-222", "total_debt": "d1#f-738", "common_shares_outstanding": "d1#f-806" }, "cash_flow": { "depreciation_and_amortization": "d1#f-311", "stock_based_compensation_expense": "d1#f-809", "operating_cash_flow": "d1#f-344", "capital_expenditures": "d1#f-1841", "payment_for_acquisitions_net_of_cash_acquired": "d1#f-356", "investing_cash_flow": "d1#f-362", "short_term_borrowing_repayment_net": "d1#f-365", "principal_payments_on_debt": "d1#f-368", "proceeds_from_issuance_of_debt": "d1#f-371", "dividends_paid": "d1#f-374", "purchases_of_treasury_shares": "d1#f-377", "proceeds_from_exercise_of_stock_options": "d1#f-380", "financing_cash_flow": "d1#f-386", "cash_and_cash_equivalents_end_of_period": "d1#f-156", "income_taxes_paid": "d1#f-401", "interest_paid": "d1#f-404" }, "segments": { "north_america": { "net_sales": "d1#f-1706", "operating_profit": "d1#f-1710" }, "latin_america": { "net_sales": "d1#f-1711", "operating_profit": "d1#f-1715" }, "europe": { "net_sales": "d1#f-1716", "operating_profit": "d1#f-1720" }, "asia_pacific": { "net_sales": "d1#f-1721", "operating_profit": "d1#f-1725" }, "africa_eurasia": { "net_sales": "d1#f-1726", "operating_profit": "d1#f-1730" }, "pet_nutrition": { "net_sales": "d1#f-1733", "operating_profit": "d1#f-1737" }, "total_oral_personal_and_home_care": { "net_sales": "d1#f-1731", "operating_profit": "d1#f-1732" }, "corporate": { "operating_profit": "d1#f-1738" }, "total": { "net_sales": "d1#f-73", "operating_profit": "d1#f-91" } }, "segments_recast_to_2026_structure": { "latin_america": { "net_sales": "d1#f-1711", "operating_profit": "d1#f-1715" }, "pet_nutrition": { "net_sales": "d1#f-1733", "operating_profit": "d1#f-1737" }, "total_oral_personal_and_home_care": { "net_sales": "d1#f-1731", "operating_profit": "d1#f-1732" }, "corporate": { "operating_profit": "d1#f-1738" }, "total": { "net_sales": "d1#f-73", "operating_profit": "d1#f-91" } }, "non_gaap": { "adjustments_to_net_income": { "acquisition_related_costs": "d1#f-1933" } } }, { "period_end": "2024-12-31", "income_statement": { "net_sales": "d1#f-74", "cost_of_sales": "d1#f-77", "gross_profit": "d1#f-80", "selling_general_and_administrative_expenses": "d1#f-83", "other_income_expense_net": "d1#f-86", "operating_profit": "d1#f-92", "non_service_related_postretirement_costs": "d1#f-95", "interest_expense": "d1#f-98", "interest_income": "d1#f-101", "income_before_income_taxes": "d1#f-104", "provision_for_income_taxes": "d1#f-107", "net_income_including_noncontrolling_interests": "d1#f-110", "net_income_attributable_to_noncontrolling_interests": "d1#f-114", "net_income": "d1#f-117", "basic_eps": "d1#f-120", "diluted_eps": "d1#f-123", "basic_shares": "d1#f-1642", "diluted_shares": "d1#f-1654", "dividends_declared_per_share": "d1#f-259" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-157", "receivables_net": "d1#f-161", "inventories": "d1#f-163", "other_current_assets": "d1#f-165", "total_current_assets": "d1#f-167", "property_plant_and_equipment_net": "d1#f-169", "goodwill": "d1#f-171", "other_intangible_assets_net": "d1#f-173", "deferred_income_tax_assets": "d1#f-175", "other_assets": "d1#f-177", "total_assets": "d1#f-179", "debt_payable_within_one_year": "d1#f-181", "accounts_payable": "d1#f-183", "accrued_income_taxes": "d1#f-185", "other_accruals": "d1#f-187", "total_current_liabilities": "d1#f-189", "long_term_debt": "d1#f-191", "deferred_income_tax_liabilities": "d1#f-193", "other_liabilities": "d1#f-195", "total_liabilities": "d1#f-197", "common_stock": "d1#f-207", "additional_paid_in_capital": "d1#f-209", "retained_earnings": "d1#f-211", "accumulated_other_comprehensive_loss": "d1#f-213", "treasury_stock_at_cost": "d1#f-215", "total_colgate_palmolive_shareholders_equity": "d1#f-217", "noncontrolling_interests": "d1#f-219", "total_equity": "d1#f-221", "total_liabilities_and_equity": "d1#f-223", "total_debt": "d1#f-739", "common_shares_outstanding": "d1#f-798" }, "cash_flow": { "depreciation_and_amortization": "d1#f-312", "stock_based_compensation_expense": "d1#f-810", "operating_cash_flow": "d1#f-345", "capital_expenditures": "d1#f-1842", "investing_cash_flow": "d1#f-363", "short_term_borrowing_repayment_net": "d1#f-366", "principal_payments_on_debt": "d1#f-369", "proceeds_from_issuance_of_debt": "d1#f-372", "dividends_paid": "d1#f-375", "purchases_of_treasury_shares": "d1#f-378", "proceeds_from_exercise_of_stock_options": "d1#f-381", "financing_cash_flow": "d1#f-387", "cash_and_cash_equivalents_end_of_period": "d1#f-157", "income_taxes_paid": "d1#f-402", "interest_paid": "d1#f-405" }, "segments": { "north_america": { "net_sales": "d1#f-1743", "operating_profit": "d1#f-1747" }, "latin_america": { "net_sales": "d1#f-1748", "operating_profit": "d1#f-1752" }, "europe": { "net_sales": "d1#f-1753", "operating_profit": "d1#f-1757" }, "asia_pacific": { "net_sales": "d1#f-1758", "operating_profit": "d1#f-1762" }, "africa_eurasia": { "net_sales": "d1#f-1763", "operating_profit": "d1#f-1767" }, "pet_nutrition": { "net_sales": "d1#f-1770", "operating_profit": "d1#f-1774" }, "total_oral_personal_and_home_care": { "net_sales": "d1#f-1768", "operating_profit": "d1#f-1769" }, "corporate": { "operating_profit": "d1#f-1775" }, "total": { "net_sales": "d1#f-74", "operating_profit": "d1#f-92" } }, "segments_recast_to_2026_structure": { "latin_america": { "net_sales": "d1#f-1748", "operating_profit": "d1#f-1752" }, "pet_nutrition": { "net_sales": "d1#f-1770", "operating_profit": "d1#f-1774" }, "total_oral_personal_and_home_care": { "net_sales": "d1#f-1768", "operating_profit": "d1#f-1769" }, "corporate": { "operating_profit": "d1#f-1775" }, "total": { "net_sales": "d1#f-74", "operating_profit": "d1#f-92" } }, "non_gaap": { "adjustments_to_net_income": { "restructuring_programs": "d1#f-534" } } }, { "period_end": "2023-12-31", "income_statement": { "net_sales": "d1#f-75", "cost_of_sales": "d1#f-78", "gross_profit": "d1#f-81", "selling_general_and_administrative_expenses": "d1#f-84", "other_income_expense_net": "d1#f-87", "operating_profit": "d1#f-93", "non_service_related_postretirement_costs": "d1#f-96", "interest_expense": "d1#f-99", "interest_income": "d1#f-102", "income_before_income_taxes": "d1#f-105", "provision_for_income_taxes": "d1#f-403", "net_income_including_noncontrolling_interests": "d1#f-111", "net_income_attributable_to_noncontrolling_interests": "d1#f-115", "net_income": "d1#f-118", "basic_eps": "d1#f-121", "diluted_eps": "d1#f-124", "basic_shares": "d1#f-1645", "diluted_shares": "d1#f-1657", "dividends_declared_per_share": "d1#f-235" }, "cash_flow": { "depreciation_and_amortization": "d1#f-313", "stock_based_compensation_expense": "d1#f-811", "operating_cash_flow": "d1#f-346", "capital_expenditures": "d1#f-1843", "investing_cash_flow": "d1#f-364", "short_term_borrowing_repayment_net": "d1#f-367", "principal_payments_on_debt": "d1#f-370", "proceeds_from_issuance_of_debt": "d1#f-373", "dividends_paid": "d1#f-376", "purchases_of_treasury_shares": "d1#f-379", "proceeds_from_exercise_of_stock_options": "d1#f-382", "financing_cash_flow": "d1#f-388", "cash_and_cash_equivalents_end_of_period": "d1#f-396", "income_taxes_paid": "d1#f-403", "interest_paid": "d1#f-406" }, "segments": { "north_america": { "net_sales": "d1#f-1780", "operating_profit": "d1#f-1784" }, "latin_america": { "net_sales": "d1#f-1785", "operating_profit": "d1#f-1789" }, "europe": { "net_sales": "d1#f-1790", "operating_profit": "d1#f-1794" }, "asia_pacific": { "net_sales": "d1#f-1795", "operating_profit": "d1#f-1799" }, "africa_eurasia": { "net_sales": "d1#f-1800", "operating_profit": "d1#f-1804" }, "pet_nutrition": { "net_sales": "d1#f-1807", "operating_profit": "d1#f-1811" }, "total_oral_personal_and_home_care": { "net_sales": "d1#f-1805", "operating_profit": "d1#f-1806" }, "corporate": { "operating_profit": "d1#f-1812" }, "total": { "net_sales": "d1#f-75", "operating_profit": "d1#f-93" } }, "segments_recast_to_2026_structure": { "latin_america": { "net_sales": "d1#f-1785", "operating_profit": "d1#f-1789" }, "pet_nutrition": { "net_sales": "d1#f-1807", "operating_profit": "d1#f-1811" }, "total_oral_personal_and_home_care": { "net_sales": "d1#f-1805", "operating_profit": "d1#f-1806" }, "corporate": { "operating_profit": "d1#f-1812" }, "total": { "net_sales": "d1#f-75", "operating_profit": "d1#f-93" } } } ], "quarterly": [ { "period_end": "2026-09-30", "income_statement": { "net_sales": "d2#f-42", "cost_of_sales": "d2#f-46", "gross_profit": "d2#f-50", "selling_general_and_administrative_expenses": "d2#f-54", "other_income_expense_net": "d2#f-58", "operating_profit": "d2#f-62", "non_service_related_postretirement_costs": "d2#f-66", "interest_expense": "d2#f-70", "interest_income": "d2#f-74", "income_before_income_taxes": "d2#f-78", "provision_for_income_taxes": "d2#f-82", "net_income_including_noncontrolling_interests": "d2#f-86", "net_income_attributable_to_noncontrolling_interests": "d2#f-90", "net_income": "d2#f-94", "basic_eps": "d2#f-98", "diluted_eps": "d2#f-102", "basic_shares": "d2#f-540", "diluted_shares": "d2#f-548", "dividends_declared_per_share": "d2#f-289" }, "balance_sheet": { "cash_and_cash_equivalents": "d2#f-146", "receivables_net": "d2#f-150", "inventories": "d2#f-152", "other_current_assets": "d2#f-154", "total_current_assets": "d2#f-156", "property_plant_and_equipment_net": "d2#f-162", "goodwill": "d2#f-164", "other_intangible_assets_net": "d2#f-166", "deferred_income_tax_assets": "d2#f-168", "other_assets": "d2#f-170", "total_assets": "d2#f-172", "debt_payable_within_one_year": "d2#f-174", "accounts_payable": "d2#f-176", "accrued_income_taxes": "d2#f-178", "other_accruals": "d2#f-180", "total_current_liabilities": "d2#f-182", "long_term_debt": "d2#f-184", "deferred_income_tax_liabilities": "d2#f-186", "other_liabilities": "d2#f-188", "total_liabilities": "d2#f-190", "common_stock": "d2#f-198", "additional_paid_in_capital": "d2#f-200", "retained_earnings": "d2#f-202", "accumulated_other_comprehensive_loss": "d2#f-204", "treasury_stock_at_cost": "d2#f-206", "total_colgate_palmolive_shareholders_equity": "d2#f-208", "noncontrolling_interests": "d2#f-210", "total_equity": "d2#f-212", "total_liabilities_and_equity": "d2#f-214", "total_debt": "d2#f-989", "common_shares_outstanding": "d2#f-36" }, "cash_flow": { "capital_expenditures": "d2#f-921", "depreciation_and_amortization": "d2#f-953" }, "segments": { "north_america": { "net_sales": "d2#f-753", "operating_profit": "d2#f-757" }, "latin_america": { "net_sales": "d2#f-758", "operating_profit": "d2#f-762" }, "europe_middle_east_and_africa": { "net_sales": "d2#f-763", "operating_profit": "d2#f-186" }, "asia_pacific": { "net_sales": "d2#f-768", "operating_profit": "d2#f-772" }, "pet_nutrition": { "net_sales": "d2#f-775", "operating_profit": "d2#f-779" }, "total_oral_personal_and_home_care": { "net_sales": "d2#f-773", "operating_profit": "d2#f-774" }, "corporate": { "operating_profit": "d2#f-780" }, "total": { "net_sales": "d2#f-42", "operating_profit": "d2#f-62" } }, "non_gaap": { "adjustments_to_net_income": { "strategic_growth_and_productivity_program": "d2#f-455" } } }, { "period_end": "2025-09-30", "income_statement": { "net_sales": "d2#f-43", "cost_of_sales": "d2#f-47", "gross_profit": "d2#f-51", "selling_general_and_administrative_expenses": "d2#f-55", "other_income_expense_net": "d2#f-59", "operating_profit": "d2#f-63", "non_service_related_postretirement_costs": "d2#f-67", "interest_expense": "d2#f-71", "interest_income": "d2#f-75", "income_before_income_taxes": "d2#f-79", "provision_for_income_taxes": "d2#f-83", "net_income_including_noncontrolling_interests": "d2#f-87", "net_income_attributable_to_noncontrolling_interests": "d2#f-91", "net_income": "d2#f-95", "basic_eps": "d2#f-99", "diluted_eps": "d2#f-103", "basic_shares": "d2#f-543", "diluted_shares": "d2#f-551", "dividends_declared_per_share": "d2#f-315" }, "cash_flow": { "capital_expenditures": "d2#f-922", "depreciation_and_amortization": "d2#f-954" }, "segments": { "north_america": { "net_sales": "d2#f-813", "operating_profit": "d2#f-817" }, "latin_america": { "net_sales": "d2#f-818", "operating_profit": "d2#f-822" }, "europe_middle_east_and_africa": { "net_sales": "d2#f-823", "operating_profit": "d2#f-827" }, "asia_pacific": { "net_sales": "d2#f-828", "operating_profit": "d2#f-832" }, "pet_nutrition": { "net_sales": "d2#f-835", "operating_profit": "d2#f-839" }, "total_oral_personal_and_home_care": { "net_sales": "d2#f-833", "operating_profit": "d2#f-79" }, "corporate": { "operating_profit": "d2#f-840" }, "total": { "net_sales": "d2#f-43", "operating_profit": "d2#f-63" } }, "non_gaap": { "adjusted_income_before_income_taxes": "d2#f-79", "adjusted_net_income": "d2#f-95", "adjusted_diluted_eps": "d2#f-103" } } ], "year_to_date": { "income_statement": { "net_sales": "d2#f-44", "cost_of_sales": "d2#f-48", "gross_profit": "d2#f-52", "selling_general_and_administrative_expenses": "d2#f-56", "other_income_expense_net": "d2#f-60", "operating_profit": "d2#f-64", "non_service_related_postretirement_costs": "d2#f-68", "interest_expense": "d2#f-72", "interest_income": "d2#f-76", "income_before_income_taxes": "d2#f-80", "provision_for_income_taxes": "d2#f-84", "net_income_including_noncontrolling_interests": "d2#f-88", "net_income_attributable_to_noncontrolling_interests": "d2#f-92", "net_income": "d2#f-96", "basic_eps": "d2#f-100", "diluted_eps": "d2#f-104", "basic_shares": "d2#f-556", "diluted_shares": "d2#f-564", "dividends_declared_per_share": "d2#f-350" }, "cash_flow": { "depreciation_and_amortization": "d2#f-218", "stock_based_compensation_expense": "d2#f-224", "operating_cash_flow": "d2#f-238", "capital_expenditures": "d2#f-923", "investing_cash_flow": "d2#f-250", "short_term_borrowing_repayment_net": "d2#f-252", "principal_payments_on_debt": "d2#f-254", "dividends_paid": "d2#f-258", "purchases_of_treasury_shares": "d2#f-260", "proceeds_from_exercise_of_stock_options": "d2#f-262", "financing_cash_flow": "d2#f-266", "cash_and_cash_equivalents_end_of_period": "d2#f-146", "income_taxes_paid": "d2#f-276", "interest_paid": "d2#f-278" }, "segments": { "north_america": { "net_sales": "d2#f-783", "operating_profit": "d2#f-787" }, "latin_america": { "net_sales": "d2#f-788", "operating_profit": "d2#f-792" }, "europe_middle_east_and_africa": { "net_sales": "d2#f-793", "operating_profit": "d2#f-797" }, "asia_pacific": { "net_sales": "d2#f-798", "operating_profit": "d2#f-802" }, "pet_nutrition": { "net_sales": "d2#f-805", "operating_profit": "d2#f-809" }, "total_oral_personal_and_home_care": { "net_sales": "d2#f-803", "operating_profit": "d2#f-804" }, "corporate": { "operating_profit": "d2#f-810" }, "total": { "net_sales": "d2#f-44", "operating_profit": "d2#f-64" } }, "non_gaap": { "adjustments_to_net_income": { "strategic_growth_and_productivity_program": "d2#f-456" } }, "prior_year_comparative": { "income_statement": { "net_sales": "d2#f-45", "cost_of_sales": "d2#f-49", "gross_profit": "d2#f-53", "selling_general_and_administrative_expenses": "d2#f-57", "other_income_expense_net": "d2#f-61", "operating_profit": "d2#f-65", "non_service_related_postretirement_costs": "d2#f-69", "interest_expense": "d2#f-73", "interest_income": "d2#f-77", "income_before_income_taxes": "d2#f-81", "provision_for_income_taxes": "d2#f-85", "net_income_including_noncontrolling_interests": "d2#f-89", "net_income_attributable_to_noncontrolling_interests": "d2#f-93", "net_income": "d2#f-97", "basic_eps": "d2#f-101", "diluted_eps": "d2#f-105", "basic_shares": "d2#f-559", "diluted_shares": "d2#f-567", "dividends_declared_per_share": "d2#f-375" }, "cash_flow": { "depreciation_and_amortization": "d2#f-219", "stock_based_compensation_expense": "d2#f-225", "operating_cash_flow": "d2#f-239", "capital_expenditures": "d2#f-924", "payment_for_acquisitions_net_of_cash_acquired": "d2#f-247", "investing_cash_flow": "d2#f-251", "short_term_borrowing_repayment_net": "d2#f-253", "principal_payments_on_debt": "d2#f-255", "proceeds_from_issuance_of_debt": "d2#f-257", "dividends_paid": "d2#f-259", "purchases_of_treasury_shares": "d2#f-261", "proceeds_from_exercise_of_stock_options": "d2#f-263", "financing_cash_flow": "d2#f-267", "cash_and_cash_equivalents_end_of_period": "d2#f-275", "income_taxes_paid": "d2#f-277", "interest_paid": "d2#f-279" }, "segments": { "north_america": { "net_sales": "d2#f-239", "operating_profit": "d2#f-847" }, "latin_america": { "net_sales": "d2#f-848", "operating_profit": "d2#f-852" }, "europe_middle_east_and_africa": { "net_sales": "d2#f-853", "operating_profit": "d2#f-857" }, "asia_pacific": { "net_sales": "d2#f-858", "operating_profit": "d2#f-862" }, "pet_nutrition": { "net_sales": "d2#f-865", "operating_profit": "d2#f-869" }, "total_oral_personal_and_home_care": { "net_sales": "d2#f-863", "operating_profit": "d2#f-864" }, "corporate": { "operating_profit": "d2#f-870" }, "total": { "net_sales": "d2#f-45", "operating_profit": "d2#f-65" } }, "non_gaap": { "adjustments_to_net_income": { "erisa_litigation_matter": "d2#f-377" } } } } } }